Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Kempf

Showing results (281-290 of 415) with videos related to

Pageof 42
Sort By:
Insect Molecular Biology|September 17, 2002
Developmental- and tissue-specific expression of an inhibitor of apoptosis protein 1 homologue from Aedes triseriatus mosquitoesB J Blitvich, C D Blair, B J Kempf, et al.
Journal of Virology|July 20, 2001
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsD J Kempf, J D Isaacson, M S King, et al.
Oncotarget|September 27, 2017
TNFα affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomicsPia Jensen, Christa L Myhre, Pernille S Lassen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 1995
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansD J Kempf, K C Marsh, J F Denissen, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1991
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseD J Kempf, K C Marsh, D A Paul, et al.
Journal of Medicinal Chemistry|June 1, 2018
Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 TetrahydrofuranylglycineKoushi Hidaka, Tooru Kimura, Rajesh Sankaranarayanan, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of orally bioavailable, symmetry-based inhibitors of HIV proteaseD J Kempf, K C Marsh, L C Fino, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
A Prospective Analysis of the Burden of Multi-Drug-Resistant Pathogens in Acute Appendicitis and Their Implication for Clinical ManagementFaruk Koca, Sara Fatima Faqar-Uz-Zaman, Claudia Reinheimer, et al.
Infection and Immunity|May 8, 2013
Hypoxia-inducible factor 1-regulated lysyl oxidase is involved in Staphylococcus aureus abscess formationChristiane Beerlage, Jessica Greb, Dorothee Kretschmer, et al.
Journal of Virology|March 1, 1994
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitorD D Ho, T Toyoshima, H Mo, et al.
Pageof 42

Showing results (281-290 of 415) with videos related to

Sort By:
Pageof 42
Insect Molecular Biology|September 17, 2002
Developmental- and tissue-specific expression of an inhibitor of apoptosis protein 1 homologue from Aedes triseriatus mosquitoesB J Blitvich, C D Blair, B J Kempf, et al.
Journal of Virology|July 20, 2001
Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patientsD J Kempf, J D Isaacson, M S King, et al.
Oncotarget|September 27, 2017
TNFα affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomicsPia Jensen, Christa L Myhre, Pernille S Lassen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 28, 1995
ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humansD J Kempf, K C Marsh, J F Denissen, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1991
Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 proteaseD J Kempf, K C Marsh, D A Paul, et al.
Journal of Medicinal Chemistry|June 1, 2018
Identification of Highly Potent Human Immunodeficiency Virus Type-1 Protease Inhibitors against Lopinavir and Darunavir Resistant Viruses from Allophenylnorstatine-Based Peptidomimetics with P2 TetrahydrofuranylglycineKoushi Hidaka, Tooru Kimura, Rajesh Sankaranarayanan, et al.
Bioorganic & Medicinal Chemistry|September 1, 1994
Design of orally bioavailable, symmetry-based inhibitors of HIV proteaseD J Kempf, K C Marsh, L C Fino, et al.
Antibiotics (Basel, Switzerland)|April 29, 2025
A Prospective Analysis of the Burden of Multi-Drug-Resistant Pathogens in Acute Appendicitis and Their Implication for Clinical ManagementFaruk Koca, Sara Fatima Faqar-Uz-Zaman, Claudia Reinheimer, et al.
Infection and Immunity|May 8, 2013
Hypoxia-inducible factor 1-regulated lysyl oxidase is involved in Staphylococcus aureus abscess formationChristiane Beerlage, Jessica Greb, Dorothee Kretschmer, et al.
Journal of Virology|March 1, 1994
Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitorD D Ho, T Toyoshima, H Mo, et al.
Pageof 42